Imunon, INC Form 4 insider transactions

Imunon, Inc. director Christine A. Pellizzari was granted 4,827 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc. Director Donald P. Braun was granted 5,881 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc. Director James E. Dentzer was granted 4,405 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc.'s Executive Chairman, Michael H. Tardugno, acquired 43,821 stock options with an exercise price of $3.95.

Imunon, Inc. CEO Stacy Lindborg acquired 1,667 shares of common stock through the vesting of restricted stock, increasing her direct beneficial ownership.

Imunon, Inc. Director James E. Dentzer acquired common stock and stock options on August 4, 2025, following a 1-for-15 reverse stock split effected on July 25, 2025.

Imunon Director Christine Pellizzari acquired 2,248 shares of common stock and 250 stock options, partly in lieu of cash board fees, following a recent 1-for-15 reverse stock split.

Imunon, Inc. Director Donald P. Braun acquired 2,040 shares of common stock and 250 stock options as compensation, following a 1-for-15 reverse stock split.

Imunon, Inc. director Frederick J. Fritz acquired common stock and stock options as compensation following a 1-for-15 reverse stock split.

Imunon's Chief Scientific Officer, Khursheed Anwer, acquired 1,667 stock options with an exercise price of $9.2, following a recent 1-for-15 reverse stock split.

CFO Kimberly Bragg acquired stock options in Imunon, Inc. on August 4, 2025.

Imunon's General Counsel and Corporate Secretary, Susan Eylward, was granted 417 stock options with an exercise price of $9.20, adjusted for a recent 1-for-15 reverse stock split.

Imunon, Inc.'s Executive Chairman, Michael H. Tardugno, was granted 1,667 stock options with an exercise price of $9.2, following a 1-for-15 reverse stock split.

Imunon, Inc. CEO and Director Stacy Lindborg was granted 5,000 stock options with a $9.2 exercise price, vesting over two years.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., was granted stock options for 25,000 shares on March 14, 2025, according to a Form 4 filing.

Director Frederick J. Fritz of Imunon, Inc. was granted stock options to purchase 3,750 shares of common stock at an exercise price of $0.8651 on March 14, 2025.

Director Donald P. Braun reports acquisition of stock options in Imunon, Inc.

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., acquired stock options on March 14, 2025.

James E. Dentzer, a director of Imunon, Inc., was granted stock options to purchase 3,750 shares of common stock at an exercise price of $0.8651 on March 14, 2025.

Michael Tardugno, Executive Chairman of Imunon, Inc., reports the acquisition of stock options.

Christine Pellizzari, a director of Imunon, Inc., acquired stock options exercisable for 3,750 shares of common stock at a price of $0.8651 on March 14, 2025.

Imunon's President and CEO, Stacy Lindborg, reports the acquisition of 75,000 stock options exercisable at $0.8651, vesting over two years.

Chief Medical Officer Douglas Vincent Faller receives stock options from Imunon, Inc.

Director Donald P. Braun purchased 25,000 shares of Imunon, Inc. (IMNN) common stock on August 20, 2024, at a price of $1.1792 per share.

Michael Tardugno, Executive Chairman of Imunon, Inc., was granted stock options to purchase 12,500 shares of common stock on December 18, 2024.

Stacy Lindborg, CEO of Imunon, Inc., files an amended Form 4 to report a previously unreported grant of 25,000 restricted stock units (RSUs) received on September 6, 2024.

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., reports the acquisition of stock options.

Director Donald P. Braun reports acquiring options to purchase 9,072 shares of Imunon common stock in lieu of cash board fees.

Christine A. Pellizzari, a director at Imunon, Inc., acquired stock options in lieu of cash for a portion of her board fees.

Director James E. Dentzer acquired 3,634 stock options of Imunon, Inc. in lieu of cash for a portion of board fees.